Type of publication:
Journal article
Author(s):
Aderinto N.; Olatunji G.; Kokori E.; Ogieuhi I.J.; Alao A.E.; Ajimotokan O.I.; Victoria O.O.; *Akinruli O.A.; Olawoyin M.T.
Citation:
Discover public health. 22(1) (no pagination), 2025. Article Number: 194. Date of Publication: 01 Dec 2025
Abstract:
Meningitis is a serious and potentially life-threatening condition due to inflammation of the brain and spinal cord's meninges. It has various etiologies, among which bacterial meningitis appears to be the most prevalent. Nigeria, the largest country in Africa has now become the first country to roll out a new vaccine called the Men5CV, being able to offer protective against five meningococcal bacterial strains (A, C, W, Y, and X), it offers hope to low-income and developing countries across the world. Clinical trials showed consistent efficacy with minimum adverse effects, and as such it has been approved by the World Health Organization (WHO). 1686 suspected cases were recorded within the last four years in Nigeria, with about 124 confirmed deaths. Despite the success with the MenA conjugate vaccine, other strains still persist. Through a 13-year collaborative effort, there has been significant protection. The rollout of the MEN4CV marks a critical step towards the goal of the WHO in completely eradicating meningitis by 2030. Although challenges like religious reasons and limited vaccine supply exist, we believe with effective training for healthcare practitioners and effective distribution of vaccines to remote areas, these obstacles can be overcome.
DOI: 10.1186/s12982-025-00592-9
Link to full-text [open access - no password required]
